Regeneron Pharmaceuticals, Inc. (LON:0R2M)

Regeneron Pharmaceuticals Statistics

Total Valuation

LON:0R2M has a market cap or net worth of GBP 60.47 billion. The enterprise value is 48.37 billion.

Market Cap	60.47B
Enterprise Value	48.37B

Important Dates

The next estimated earnings date is Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	Nov 20, 2025

Share Statistics

Current Share Class	100.78M
Shares Outstanding	n/a
Shares Change (YoY)	-4.39%
Shares Change (QoQ)	-1.29%
Owned by Insiders (%)	3.76%
Owned by Institutions (%)	87.91%
Float	98.56M

Valuation Ratios

The trailing PE ratio is 17.76 and the forward PE ratio is 16.99.

PE Ratio	17.76
Forward PE	16.99
PS Ratio	5.71
PB Ratio	2.63
P/TBV Ratio	2.75
P/FCF Ratio	19.25
P/OCF Ratio	16.03
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.60, with an EV/FCF ratio of 15.40.

EV / Earnings	14.20
EV / Sales	4.49
EV / EBITDA	14.60
EV / EBIT	16.75
EV / FCF	15.40

Financial Position

The company has a current ratio of 4.06, with a Debt / Equity ratio of 0.09.

Current Ratio	4.06
Quick Ratio	3.19
Debt / Equity	0.09
Debt / EBITDA	0.62
Debt / FCF	0.64
Interest Coverage	90.81

Financial Efficiency

Return on equity (ROE) is 15.19% and return on invested capital (ROIC) is 7.27%.

Return on Equity (ROE)	15.19%
Return on Assets (ROA)	6.16%
Return on Invested Capital (ROIC)	7.27%
Return on Capital Employed (ROCE)	10.70%
Revenue Per Employee	696,328
Profits Per Employee	223,739
Employee Count	15,106
Asset Turnover	0.37
Inventory Turnover	2.46

Taxes

In the past 12 months, LON:0R2M has paid 421.89 million in taxes.

Income Tax	421.89M
Effective Tax Rate	11.02%

Stock Price Statistics

The stock price has increased by +3.57% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+3.57%
50-Day Moving Average	631.47
200-Day Moving Average	598.53
Relative Strength Index (RSI)	77.70
Average Volume (20 Days)	1,102

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.59

Income Statement

In the last 12 months, LON:0R2M had revenue of GBP 10.60 billion and earned 3.41 billion in profits. Earnings per share was 30.94.

Revenue	10.60B
Gross Profit	4.86B
Operating Income	2.84B
Pretax Income	3.83B
Net Income	3.41B
EBITDA	3.23B
EBIT	2.84B
Earnings Per Share (EPS)	30.94

Balance Sheet

The company has 6.28 billion in cash and 2.01 billion in debt, giving a net cash position of 11.92 billion.

Cash & Cash Equivalents	6.28B
Total Debt	2.01B
Net Cash	11.92B
Net Cash Per Share	n/a
Equity (Book Value)	23.03B
Book Value Per Share	224.03
Working Capital	10.08B

Cash Flow

In the last 12 months, operating cash flow was 3.77 billion and capital expenditures -631.83 million, giving a free cash flow of 3.14 billion.

Operating Cash Flow	3.77B
Capital Expenditures	-631.83M
Free Cash Flow	3.14B
FCF Per Share	n/a

Margins

Gross margin is 45.83%, with operating and profit margins of 26.83% and 32.13%.

Gross Margin	45.83%
Operating Margin	26.83%
Pretax Margin	36.11%
Profit Margin	32.13%
EBITDA Margin	30.52%
EBIT Margin	26.83%
FCF Margin	29.63%

Dividends & Yields

This stock pays an annual dividend of 2.68, which amounts to a dividend yield of 0.34%.

Dividend Per Share	2.68
Dividend Yield	0.34%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	8.65%
Buyback Yield	4.39%
Shareholder Yield	4.73%
Earnings Yield	5.63%
FCF Yield	5.19%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0R2M has an Altman Z-Score of 6.89 and a Piotroski F-Score of 4.

Altman Z-Score	6.89
Piotroski F-Score	4